Study: Health care providers split on who should prescribe HIV prevention drug

April 30, 2019

BUFFALO, N.Y. -- Health care practitioners are split when it comes to opinions on which provider should take the lead in prescribing pre-exposure prophylaxis (PrEP), which is administered to people at high risk for HIV.

That's according to the findings of a new study by researchers from the University at Buffalo, who interviewed PrEP-prescribing providers to conduct a qualitative analysis of their perspectives on the preventive medication. Their paper was published online ahead of print earlier this month in the Journal of the Association of Nurses in AIDS Care.

In a separate study, UB researchers also surveyed pharmacy students about their knowledge of and views toward the medication.

"Understanding barriers and facilitators to PrEP adoption and implementation from both current and future health care providers is key to accelerate roll-out of this preventive medication to target populations who meet clinical eligibility criteria," said Sarahmona Przybyla, the study's lead author.

Przybyla is an assistant professor of community health and health behavior in UB's School of Public Health and Health Professions.

Who should prescribe PrEP?

In the U.S., there are more than 1.1 million people living with HIV, and 38,500 new infections occurring annually.

It has been seven years since the U.S. Food and Drug Administration approved PrEP for use in adults, and one year for adolescents. Still, previous research has shown that PrEP uptake has not met expectations. For example, the U.S. Centers for Disease Control and Prevention estimates that 1.2 million Americans are eligible for the drug, but only 150,000 take it.

PrEP is available only to people who are HIV negative. There's a debate -- dubbed the "purview paradox" -- within the health care and public health community about who should prescribe PrEP. While HIV specialists are likely to be the most willing and able to prescribe PrEP, they typically don't see HIV-uninfected patients. Meanwhile, primary care physicians are more likely to see eligible PrEP patients, but generalists may lack the training and skills necessary to prescribe it.

With this in mind, Przybyla and her team surveyed a small sample of clinicians in Erie and Niagara counties in Western New York who were licensed to prescribe medication in New York State, and who had prescribed PrEP for at least three months.

Participants were almost equally split on ideal provider type: 15 chose primary care physicians, while 13 said any health care provider. None of the participants indicated a preference for infectious disease or HIV specialists. That's likely because there are approximately 8,500 infectious disease specialists in the U.S., an insufficient number to treat the 1 million individuals who meet PrEP eligibility guidelines.

Previous studies of patients and health care providers have shown that primary care physicians are the preferred provider, largely because they're more available and accessible, and because they're more likely to see patients over a long period of time.

Clinicians are key stakeholders in PrEP engagement for patients at risk of HIV infection, according to Przybyla. "This research provides support for a growing foundation of research that warrants continued efforts to incorporate PrEP into a comprehensive HIV prevention plan at local, state, and national levels."

Surveying Rx students about PrEP

Przybyla is also the author of the first paper to survey pharmacy students about their knowledge of and attitudes toward PrEP. The study of 291 students enrolled in the pharmacy doctoral program (PharmD) in UB's School of Pharmacy and Pharmaceutical Sciences found that:Other studies have examined PrEP attitudes among pharmacists, physicians, nurse practitioners and physician assistants, as well as medical students, but none have surveyed pharmacy students, Przybyla said.

The study, published online ahead of print in the journal Currents in Pharmacy Teaching and Learning, reveals a need for increased educational efforts to improve pharmacy students' knowledge of CDC prescription guidelines for the drug.

For example, 40 percent of respondents -- a higher proportion than in previous studies of health care providers -- erroneously believed that widespread use of PrEP could significantly increase rates of antiretroviral resistance.

CDC guidelines for clinicians provide detailed evidence that drug-resistant mutations are rare, researchers note.

University at Buffalo

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to